Please select the option that best describes you:
What is your approach for perioperative chemotherapy in MSI-H/dMMR localized gastric cancer?
Exploratory analysis of the MAGIC trial suggested perioperative chemotherapy was detrimental in this subset of patients. Has availability of IO altered your practice?
Answer from: Medical Oncologist at Academic Institution
This question gets at aspects of MSI-H biology, biomarker testing and post-hoc data from the MAGIC and CLASSIC trials suggesting a lack of benefit, and potential negative impact of treatment in MSI-H patients. The following is restricted to gastric cancer, and the rates of MSI-H in true esopha...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
As ever, @Sam provides an exhaustive analysis of this topic and has the receipts/references to back it up.I would approach this answer with a slightly different emphasis. Firstly, in addition to the references he cites, there is the individual patient data meta-analysis by Pietrantonio and coll...